US74349U1088 - Common Stock - After market: 108.68 0 (0%)
SAN DIEGO, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision...
This biotech stock just jumped over 180% in a single day, and investors want to know if there could be more big gains ahead.
SAN DIEGO, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision...
The clinical-stage biotech that specializes in IBD therapies announced positive news regarding two trials for its lead therapy.
EQNX::TICKER_START (NASDAQ:ONCY),(NASDAQ:GILD),(NYSE:BMY),(NASDAQ:RXDS),(NASDAQ:RNAZ) EQNX::TICKER_END
/PRNewswire/ -- FinancialNewsMedia.com News Commentary - According to a report from Global Market Insights the Breast Cancer Therapeutics Market size, which...
CVNA plunges more than 40%. ASO climbs on earnings news. SWBI declines on quarterly results. RXDX skyrockets on clinical data.
SAN DIEGO, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision...
Pinterest (PINS) stock is on the move Wednesday as investors react to an agreement with Elliott Investment Management L.P.
Prometheus Biosciences (NASDAQ:RXDX) stock is rocketing higher on Wednesday after reporting results from two Phase 2 clinical trials.
Prometheus Biosciences made waves Wednesday in irritable bowel disease.
Even as broader markets fell, these companies announced great news.
Prometheus Biosciences (RXDX) said its medicine PRA023 showed strong efficacy and favorable safety in two mid stage trials in patients with ulcerative colitis ((UC)) and Crohn’s...